Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
about
Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapyTargeting of the GTPase Irgm1 to the phagosomal membrane via PtdIns(3,4)P(2) and PtdIns(3,4,5)P(3) promotes immunity to mycobacteria.A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding.Lipid kinases as therapeutic targets for chronic painMultiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesisA KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotypeIdentification of novel piperazinylquinoxaline derivatives as potent phosphoinositide 3-kinase (PI3K) inhibitorsRole of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets.The PIK3CA gene as a mutated target for cancer therapy.The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid.Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesisSelective and potent small-molecule inhibitors of PI3Ks.Development and application of PI3K assays for novel drug discovery.Aqueous hydrotrope: an efficient and reusable medium for a green one-pot, diversity-oriented synthesis of quinazolinone derivatives.Phosphatidylinositol-3-kinase as a therapeutic target in melanomaDrugging the PI3 kinome: from chemical tools to drugs in the clinic.Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.Antiproliferative activities of halogenated thieno[3,2-d]pyrimidinesInsulin-like growth factor-1 regulates platelet activation through PI3-Kalpha isoformDysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.A convenient route to symmetrically and unsymmetrically substituted 3,5-diaryl-2,4,6-trimethylpyridines via Suzuki-Miyaura cross-coupling reaction.Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatmentA dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.PI3K inhibitors in cardiovascular disease.Potential role of PI3K inhibitors in the treatment of breast cancer.Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?PI3K p110 alpha and p110 beta have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts.
P2860
Q24611233-D20AEF1E-322D-4413-886D-D1D4936048A2Q24644997-786D2829-0EDD-4E5D-951C-AB1B516D6CA6Q24645971-8A6FCBF6-045A-4431-93F7-F5BF8E9B36D4Q27023075-EB467711-FDBE-4050-AFAF-1821A56466CFQ27325801-E4851601-523F-4BC2-B6D3-104D146F022CQ28117127-BD560AC9-9AAE-4910-ACCD-A8EC676D63A8Q28482245-C6BE794E-8F18-45C8-A826-968252B115F6Q33495925-C38751ED-7060-49B6-8EB5-DB7578C90B59Q33699378-D984DE78-B350-46C7-81DA-F51F4695C05AQ33959529-F04BCAE3-0C5F-4151-B576-4610C873E761Q34379505-1B8AE166-0733-4189-9417-B6C89EA7F857Q34472091-BA79B90B-03AC-4AB3-8BE1-B99A13800576Q34682072-BC352A55-B251-4E3B-ABF7-BEE9D9CB0FDDQ35165157-96ED891F-87D2-4DE1-9C3E-8DA1B917E427Q35190512-4833607F-58CF-4C3E-9010-CC67EE880AF3Q35535379-B29E156F-C6F3-422E-AB51-0F019E023417Q35581668-0391BFD6-548E-425F-91A7-2D520733D666Q35606261-12FF6AC2-2FC4-40EE-BD9D-1F66EBE4CB15Q35622141-51949008-368D-4F03-BA50-2FAE59961A9FQ35781662-F3C36C3B-BF60-4E74-8711-02EAEF5CB757Q36047250-B221FC4C-29A0-451A-8B01-E22C0759DD4AQ36447899-00713736-1881-4C65-9C45-B0469419EB39Q36746834-73F25C9B-B1F6-4297-BBA5-3539CFCEE2F2Q36991912-63B8DFD7-6DED-466C-8D62-DDAE68915FF4Q36997524-D5FA8A04-1310-4FD4-852A-42283A44C194Q37003323-736DC713-7B00-4DBD-8AD0-DE3DF0A3D9DEQ37003826-987B01C1-DE4A-46AB-905C-B5C617F81EC7Q37011768-F13DCE4A-BEBF-403F-97B5-D8294BE1A691Q37281824-0709745E-3E81-4516-9F6F-E408D0873CEEQ37320140-B1867F8C-102C-42C3-A5F9-072120DC771CQ37331742-0091E1AA-42C5-4451-995C-60E09919B792Q37727180-0DEC6464-1061-4BCD-A516-22F87EF8D8CFQ37772192-48C7E021-EF4D-4690-8320-1F214E0DAAF3Q37783617-28ACD7C5-6B1F-4FF6-8030-E8D6B6037909Q38106130-4E34638A-96E8-4233-A643-972D7801DCA0Q38706839-21B6B71B-4BA6-4C40-AF72-FDA53FD0179FQ38808318-59C746AF-FED0-45EB-9008-3809B9179A1BQ38915978-267BC521-A1BD-4BE8-916C-B4E4FD1E0FEFQ38934741-08E2A29E-7324-418E-B2DF-F3A9C2B969F3Q39634639-D76415B6-4DB9-4326-AE71-6DEEC740DA9D
P2860
Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Synthesis and biological evalu ...... 3 kinase p110alpha inhibitors.
@en
type
label
Synthesis and biological evalu ...... 3 kinase p110alpha inhibitors.
@en
prefLabel
Synthesis and biological evalu ...... 3 kinase p110alpha inhibitors.
@en
P2093
P1476
Synthesis and biological evalu ...... 3 kinase p110alpha inhibitors.
@en
P2093
Hiroyuki Kaizawa
Hiroyuki Moritomo
Masahiko Hayakawa
Mike Waterfield
Minoru Okada
Mitsuaki Ohta
Peter Parker
Shin-ichi Tsukamoto
Takahide Ohishi
Tomonobu Koizumi
P304
P356
10.1016/J.BMC.2006.06.046
P407
P50
P577
2006-07-11T00:00:00Z